Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions

OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indicat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gynecol Oncol
Autors principals: Maurer, Kathryn, Michener, Chad, Mahdi, Haider, Rose, Peter G.
Format: Artigo
Idioma:Inglês
Publicat: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447141/
https://ncbi.nlm.nih.gov/pubmed/28541630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2017.28.e38
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars